Matching Items (10)
Filtering by
- All Subjects: Drug Delivery
- All Subjects: Biomarkers
- Creators: Anderson, Karen
Description
Introduction: Human papillomavirus (HPV) infection is seen in up to 90% of cases of cervical cancer, the third leading cancer cause of death in women. Current HPV screening focuses on only two HPV types and covers roughly 75% of HPV-associated cervical cancers. A protein based assay to test for antibody biomarkers against 98 HPV antigens from both high and low risk types could provide an inexpensive and reliable method to screen for patients at risk of developing invasive cervical cancer. Methods: 98 codon optimized, commercially produced HPV genes were cloned into the pANT7_cGST vector, amplified in a bacterial host, and purified for mammalian expression using in vitro transcription/translation (IVTT) in a luminescence-based RAPID ELISA (RELISA) assay. Monoclonal antibodies were used to determine immune cross-reactivity between phylogenetically similar antigens. Lastly, several protein characteristics were examined to determine if they correlated with protein expression. Results: All genes were successfully moved into the destination vector and 86 of the 98 genes (88%) expressed protein at an adequate level. A difference was noted in expression by gene across HPV types but no correlation was found between protein size, pI, or aliphatic index and expression. Discussion: Further testing is needed to express the remaining 12 HPV genes. Once all genes have been successfully expressed and purified at high concentrations, DNA will be printed on microscope slides to create a protein microarray. This microarray will be used to screen HPV-positive patient sera for antibody biomarkers that may be indicative of cervical cancer and precancerous cervical neoplasias.
ContributorsMeshay, Ian Matthew (Author) / Anderson, Karen (Thesis director) / Magee, Mitch (Committee member) / Katchman, Benjamin (Committee member) / Barrett, The Honors College (Contributor) / School of Life Sciences (Contributor)
Created2015-05
Description
With microspheres growing in popularity as viable systems for targeted drug therapeutics, there exist a host of diseases and pathology induced side effects which could be treated with poly(lactic-co-glycolic acid) [PLGA] microparticle systems [6,10,12]. While PLGA systems are already applied in a wide variety the clinical setting [11], microparticles still have some way to go before they are viable systems for drug delivery. One of the main reasons for this is a lack of fabrication processes and systems which produce monodisperse particles while also being feasible for industrialization [10]. This honors thesis investigates various microparticle fabrication techniques \u2014 two using mechanical agitation and one using fluid dynamics \u2014 with the long term goal of incorporating norepinephrine and adenosine into the particles for metabolic stimulatory purposes. It was found that mechanical agitation processes lead to large values for dispersity and the polydispersity index while fluid dynamics methods have the potential to create more uniform and predictable outcomes. The research concludes by needing further investigation into methods and prototype systems involving fluid dynamics methods; however, these systems yield promising results for fabricating monodisperse particles which have the potential to encapsulate a wide variety of therapeutic drugs.
ContributorsRiley, Levi Louis (Author) / Vernon, Brent (Thesis director) / VanAuker, Michael (Committee member) / Harrington Bioengineering Program (Contributor) / Barrett, The Honors College (Contributor)
Created2018-12
Description
Background: Recent interests in continuous biomonitoring and the surge of wearable biotechnology demand a better understanding of sweat as a noninvasive biomarker resource. The ability to use sweat as a biofluid provides the opportunity for noninvasive early and continuous diagnostics. This thesis serves to help fill the existing knowledge gap in sweat biomarker discovery and applications.
Experimental Design: In part one of this study, exercise-induced eccrine sweat was collected from 50 healthy individuals and analyzed using mass spectrometry, protein microarrays, and quantitative ELISAs to identify a broad range of proteins, antibody isotypes, and cytokines in sweat. In part two of this study, cortisol and melatonin levels were analyzed in exercise-induced sweat and plasma samples collected from 22 individuals.
Results: 220 unique proteins were identified by shotgun analysis in pooled sweat samples. Detectable antibody isotypes include IgA (100% positive; median 1230 ± 28 700 pg/mL), IgD (18%; 22.0 ± 119 pg/mL), IgG1 (96%;1640 ± 6750 pg/mL), IgG2 (37%; 292 ± 6810 pg/mL), IgG3 (71%;74.0 ± 119 pg/mL), IgG4 (69%; 43.0 ± 42.0 pg/mL), and IgM (41%;69.0 ± 1630 pg/mL). Of 42 cytokines, three were readily detected in all sweat samples (p<0.01). The median concentration for interleukin-1α was 352 ± 521 pg/mL, epidermal growth factor was 86.5 ± 147 pg/mL, and angiogenin was 38.3 ± 96.3 pg/mL. Multiple other cytokines were detected at lower levels. The median and standard deviation of cortisol was determined to be 4.17 ± 11.1 ng/mL in sweat and 76.4 ± 28.8 ng/mL in plasma. The correlation between sweat and plasma cortisol levels had an R-squared value of 0.0802 (excluding the 2 highest sweat cortisol levels). The median and standard deviation of melatonin was determined to be 73.1 ± 198 pg/mL in sweat and 194 ± 93.4 pg/mL in plasma. Similar to cortisol, the correlation between sweat and plasma melatonin had an R-squared value of 0.117.
Conclusion: These studies suggest that sweat holds more proteomic and hormonal biomarkers than previously thought and may eventually serve as a noninvasive biomarker resource. These studies also highlight many of the challenges associated with monitoring sweat content including differences between collection devices and hydration, evaporation losses, and sweat rate.
Experimental Design: In part one of this study, exercise-induced eccrine sweat was collected from 50 healthy individuals and analyzed using mass spectrometry, protein microarrays, and quantitative ELISAs to identify a broad range of proteins, antibody isotypes, and cytokines in sweat. In part two of this study, cortisol and melatonin levels were analyzed in exercise-induced sweat and plasma samples collected from 22 individuals.
Results: 220 unique proteins were identified by shotgun analysis in pooled sweat samples. Detectable antibody isotypes include IgA (100% positive; median 1230 ± 28 700 pg/mL), IgD (18%; 22.0 ± 119 pg/mL), IgG1 (96%;1640 ± 6750 pg/mL), IgG2 (37%; 292 ± 6810 pg/mL), IgG3 (71%;74.0 ± 119 pg/mL), IgG4 (69%; 43.0 ± 42.0 pg/mL), and IgM (41%;69.0 ± 1630 pg/mL). Of 42 cytokines, three were readily detected in all sweat samples (p<0.01). The median concentration for interleukin-1α was 352 ± 521 pg/mL, epidermal growth factor was 86.5 ± 147 pg/mL, and angiogenin was 38.3 ± 96.3 pg/mL. Multiple other cytokines were detected at lower levels. The median and standard deviation of cortisol was determined to be 4.17 ± 11.1 ng/mL in sweat and 76.4 ± 28.8 ng/mL in plasma. The correlation between sweat and plasma cortisol levels had an R-squared value of 0.0802 (excluding the 2 highest sweat cortisol levels). The median and standard deviation of melatonin was determined to be 73.1 ± 198 pg/mL in sweat and 194 ± 93.4 pg/mL in plasma. Similar to cortisol, the correlation between sweat and plasma melatonin had an R-squared value of 0.117.
Conclusion: These studies suggest that sweat holds more proteomic and hormonal biomarkers than previously thought and may eventually serve as a noninvasive biomarker resource. These studies also highlight many of the challenges associated with monitoring sweat content including differences between collection devices and hydration, evaporation losses, and sweat rate.
ContributorsZhu, Meilin (Author) / Anderson, Karen (Thesis director) / Blain Christen, Jennifer (Committee member) / Gronowski, Ann (Committee member) / School of Molecular Sciences (Contributor) / Barrett, The Honors College (Contributor)
Created2019-05
Description
Human papillomavirus (HPV) is the causative agent of cervical cancer. Persistent infection with high-risk HPV 16, 18 or 45 species is associated with the development and progression of cervical cancer. HPV genotyping and Pap smear tests are the regular methods used to detect pre-invasive cervical lesions, but there is a need for developing a rapid biomarker to profile immunity to these viruses. The viral E7 oncogene is expressed in most HPV-associated cancers and anti-E7 antibodies can be detected in the blood of patients with cervical cancer. This research was focused on viral E7 oncogene expression to be used in development of low-cost point of care tests, enabling patients from low resource settings to detect the asymptotic stage of cervical cancer and be able to seek treatment early. In order to produce the E7 protein in vitro to measure antibody levels, GST tagged E7 genes from HPV 16, 18 and 45 species were inserted into the pDEST15 vector and expressed in E. coli BL21DE3 cells that were induced with 1mM of IPTG. The E7-GST fused expressed protein was then purified using glutathione beads and resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein expression was 5.8 \u03bcg/ml for HPV 16E7 in 500 ml culture and for the 500 ml culture of HPV 18 E7 and 45 E7 were 10.5 \u03bcg/ml and 10.5 \u03bcg/ml for HPV 18E7 and 45E7 respectively. High yield values are showing high expression levels of GST-tagged E7 recombinant protein which can be used for serotyping a number of individuals. This shows that HPV E7 can be produced in large quantities that can potentially be used in point of care tests that can help identify women at risk of cervical cancer. In conclusion, the E7 protein produced in this study can potentially be used to induce humoral responses in patients\u2019 sera for understanding the immune response of cervical cancer.
ContributorsMakuyana, Ntombizodwa (Author) / Anderson, Karen (Thesis director) / Ewaisha, Radwa (Committee member) / Varsani, Arvind (Committee member) / Hou, Ching-Wen (Committee member) / School of Mathematical and Statistical Sciences (Contributor) / School of Molecular Sciences (Contributor) / Barrett, The Honors College (Contributor)
Created2018-12
Description
Locomotion of microorganisms is commonly observed in nature. Although microorganism locomotion is commonly attributed to mechanical deformation of solid appendages, in 1956 Nobel Laureate Peter Mitchell proposed that an asymmetric ion flux on a bacterium's surface could generate electric fields that drive locomotion via self-electrophoresis. Recent advances in nanofabrication have enabled the engineering of synthetic analogues, bimetallic colloidal particles, that swim due to asymmetric ion flux originally proposed by Mitchell. Bimetallic colloidal particles swim through aqueous solutions by converting chemical fuel to fluid motion through asymmetric electrochemical reactions. This dissertation presents novel bimetallic motor fabrication strategies, motor functionality, and a study of the motor collective behavior in chemical concentration gradients. Brownian dynamics simulations and experiments show that the motors exhibit chemokinesis, a motile response to chemical gradients that results in net migration and concentration of particles. Chemokinesis is typically observed in living organisms and distinct from chemotaxis in that there is no particle directional sensing. The synthetic motor chemokinesis observed in this work is due to variation in the motor's velocity and effective diffusivity as a function of the fuel and salt concentration. Static concentration fields are generated in microfluidic devices fabricated with porous walls. The development of nanoscale particles that swim autonomously and collectively in chemical concentration gradients can be leveraged for a wide range of applications such as directed drug delivery, self-healing materials, and environmental remediation.
ContributorsWheat, Philip Matthew (Author) / Posner, Jonathan D (Thesis advisor) / Phelan, Patrick (Committee member) / Chen, Kangping (Committee member) / Buttry, Daniel (Committee member) / Calhoun, Ronald (Committee member) / Arizona State University (Publisher)
Created2011
Description
Oropharyngeal cancer (OPC) is the world's sixth most common cancer and in many cases is associated with infection with human papillomavirus (HPV) type 16. Antibodies (Abs) to HPV16 viral antigens are potential diagnostic biomarkers of HPV-associated OPC (HPV OPC). A custom multiplexed bead array assay was used to detect Abs to HPV16 antigens E1, CE2, NE2, E4, E5, E6, E7, L1, and L2. Following extensive optimization of the assay, these genes were expressed as GST-fusion proteins and captured onto anti-GST magnetic beads. Serum was obtained from 256 OPC patients at the time of diagnosis and from 78 healthy controls. The median fluorescent intensity (MFI) was determined for each antigen and ratios of MFI to control GST-fusion protein were determined for each serum sample. Cutoff values were set as the mean + 3 SD of the MFIs of healthy controls and p-values were calculated using Wilcoxon unpaired and Fisher's exact test. Results of this experiment showed that HPV16 E1, CE2, NE2, E4, E6, and E7 Ab levels were elevated in OPC patients compared to controls (p<0.001), as were Ab levels to L1 (p = 0.013) and L2 (p = 0.023), per Fischer's exact test. Abs to CE2, NE2, E6, and E7 were identified as a potential biomarker panel for early detection of HPV OPC. For the 111 patients with known HPV+ tumors as measured by tumor PCR of E6 and/or E7, this assay had a sensitivity of 90% and specificity of 87% (AUC = 0.96). From these results, we conclude that custom bead array assays can be used to detect HPV16 Abs in patient sera, and we have identified a 4-Ab biomarker panel for the early detection of HPV OPC.
ContributorsGoulder, Alison Leigh (Author) / Anderson, Karen (Thesis director) / Lake, Douglas (Committee member) / Cheng, Julia (Committee member) / Barrett, The Honors College (Contributor) / School of Life Sciences (Contributor)
Created2013-05
Description
Polymer drug delivery system offers a key to a glaring issue in modern administration routes of drugs and biologics. Poly(lactic-co-glycolic acid) (PLGA) can be used to encapsulate drugs and biologics and deliver them into the patient, which allows high local concentration (compared to current treatment methods), protection of the cargo from the bodily environment, and reduction in systemic side effects. This experiment used a single emulsion technique to encapsulate L-tyrosine in PLGA microparticles and UV spectrophotometry to analyze the drug release over a period of one week. The release assay found that for the tested samples, the released amount is distinct initially, but is about the same after 4 days, and they generally follow the same normalized percent released pattern. The experiment could continue with testing more samples, test the same samples for a longer duration, and look into higher w/w concentrations such as 20% or 50%.
ContributorsSeo, Jinpyo (Author) / Vernon, Brent (Thesis director) / Pal, Amrita (Committee member) / Dean, W.P. Carey School of Business (Contributor) / Harrington Bioengineering Program (Contributor) / Barrett, The Honors College (Contributor)
Created2021-05
Description
Autoimmunity develops when the immune system targets self-antigens within the body. Rheumatoid arthritis (RA) is a common autoimmune disease, and its progression is characterized by pro-inflammatory immune cells rapidly proliferating, migrating, and infiltrating joint tissue to provoke inflammation. In order to fulfill this taxing autoreactive response, an increase in energy metabolism is required by immune cells, such as dendritic cells (DCs). Therefore, a shift in DC energy reliance from the Krebs cycle toward glycolysis occurs. This metabolic shift phenotypically transitions DCs from anti-inflammatory properties toward an aggressive pro-inflammatory phenotype, in turn activating pro-inflammatory T cells and promoting RA pathogenesis. If the disease persists uncontrollably, further complications and eventual joint dysfunction can occur. Although, clinically approved drugs can prevent RA progression, they require frequent administration for temporary symptom relief. Furthermore, current approved biological products for RA are not known to have a direct modulatory effect on immunometabolism. Given that cellular metabolism controls immune cell function, this work aims to harness perturbations within RA immune cell energy metabolism and utilizes it as a therapeutic target by reprogramming immune cell metabolism via the delivery of metabolite-based particles. The two-time delivery of these particles reduced RA inflammation in a RA collagen-induced arthritis (CIA) mouse model and generated desired responses with long-term effects. Specifically, this work was achieved by:
Aim 1 – developing and delivering metabolite-based polymeric microparticles synthesized from the Krebs cycle metabolite, alpha-ketoglutarate (aKG; termed paKG MPs) to DCs to modulate their energy metabolism and promote anti-inflammatory properties (in context of RA).
Aim 2 – exploiting the encapsulation ability of paKG MPs to inhibit DC glycolysis in the presence of the CIA self-antigen (collagen type II (bc2)) for the treatment of RA in CIA mice. Herein, paKG MPs encapsulating a glycolytic inhibitor and bc2 induce an anti-inflammatory DC phenotype in vitro and generate suppressive bc2-specific T cell responses and reduce paw inflammation in CIA mice.
ContributorsMangal, Joslyn Lata (Author) / Acharya, Abhinav P (Thesis advisor) / Florsheim, Esther B (Committee member) / Wu, Hsin-Jung Joyce (Committee member) / Anderson, Karen (Committee member) / Arizona State University (Publisher)
Created2022
Description
Glioblastoma (GBM) is a highly invasive and deadly late stage tumor that develops from abnormal astrocytes in the brain. With few improvements in treatment over many decades, median patient survival is only 15 months and the 5-year survival rate hovers at 6%. Numerous challenges are encountered in the development of treatments for GBM. The blood-brain barrier (BBB) serves as a primary obstacle due to its innate ability to prevent unwanted molecules, such as most chemotherapeutics, from entering the brain tissue and reaching malignant cells. The GBM cells themselves serve as a second obstacle, having a high level of genetic and phenotypic heterogeneity. This characteristic improves the probability of a population of cells to have resistance to treatment, which ensures the survival of the tumor. Here, the development and testing of two different modes of therapy for treating GBM is described. These therapeutics were enhanced by pathogenic peptides known to improve entry into brain tissue or to bind GBM cells to overcome the BBB and/or tumor cell heterogeneity. The first therapeutic utilizes a small peptide, RVG-29, derived from the rabies virus glycoprotein to improve brain-specific delivery of nanoparticles encapsulated with a small molecule payload. RVG-29-targeted nanoparticles were observed to reach the brain of healthy mice in higher concentrations 2 hours following intravenous injection compared to control particles. However, targeted camptothecin-loaded nanoparticles were not capable of producing significant treatment benefits compared to non-targeted particles in an orthotopic mouse model of GBM. Peptide degradation following injection was shown to be a likely cause for reduced treatment benefit. The second therapeutic utilizes chlorotoxin, a non-toxic 36-amino acid peptide found in the venom of the deathstalker scorpion, expressed as a fusion to antibody fragments to enhance T cell recognition and killing of GBM. This candidate biologic, known as anti-CD3/chlorotoxin (ACDClx) is expressed as an insoluble protein in Nicotiana benthamiana and Escherichia coli and must be purified in denaturing and reducing conditions prior to being refolded. ACDClx was shown to selectively activate T cells only in the presence of GBM cells, providing evidence that further preclinical development of ACDClx as a GBM immunotherapy is warranted.
ContributorsCook, Rebecca Leanne (Author) / Blattman, Joseph N (Thesis advisor) / Sirianni, Rachael W. (Thesis advisor) / Mor, Tsafrir (Committee member) / Anderson, Karen (Committee member) / Arizona State University (Publisher)
Created2019
Description
Originally conceived as a way to scaffold molecules of interest into three-dimensional (3D) crystalline lattices for X ray crystallography, the field of deoxyribonucleic acid (DNA) nanotechnology has dramatically evolved since its inception. The unique properties of DNA nanostructures have promoted their use not only for X ray crystallography, but for a suite of biomedical applications as well. The work presented in this dissertation focuses on both of these exciting applications in the field: 1) Nucleic acid nanostructures as multifunctional drug and vaccine delivery platforms, and 2) 3D DNA crystals for structure elucidation of scaffolded guest molecules.Chapter 1 illustrates how a wide variety of DNA nanostructures have been developed for the delivery of drugs and vaccine components. However, their applications are limited under physiological conditions due to their lack of stability in low salt environments, susceptibility to enzymatic degradation, and tendency for endosomal entrapment. To address these issues, Chapter 2 describes a PEGylated peptide coating molecule was designed to electrostatically adhere to and protect DNA origami nanostructures and to facilitate their cytosolic delivery by peptide-mediated endosomal escape. The development of this molecule will aid in the use of nucleic acid nanostructures for biomedical purposes, such as the delivery of messenger ribonucleic acid (mRNA) vaccine constructs. To this end, Chapter 3 discusses the fabrication of a structured mRNA nanoparticle for more cost-efficient mRNA vaccine manufacture and proposes a multi-epitope mRNA nanostructure vaccine design for targeting human papillomavirus (HPV) type 16-induced head and neck cancers.
DNA nanotechnology was originally envisioned to serve as three-dimensional scaffolds capable of positioning proteins in a rigid array for their structure elucidation by X ray crystallography. Accordingly, Chapter 4 explores design parameters, such as sequence and Holliday junction isomeric forms, for efficient crystallization of 3D DNA lattices. Furthermore, previously published DNA crystal motifs are used to site-specifically position and structurally evaluate minor groove binding molecules with defined occupancies. The results of this study provide significant advancement towards the ultimate goal of the field.
ContributorsHenry, Skylar J.W. (Author) / Stephanopoulos, Nicholas (Thesis advisor) / Anderson, Karen (Thesis advisor) / Blattman, Joseph (Committee member) / Yan, Hao (Committee member) / Arizona State University (Publisher)
Created2023